Anal human papillomavirus infections in young unvaccinated men who have sex with men attending a sexual health clinic for HPV vaccination in Melbourne, Australia

Vaccine ◽  
2019 ◽  
Vol 37 (43) ◽  
pp. 6271-6275 ◽  
Author(s):  
Eric P.F. Chow ◽  
Jennifer A. Danielewski ◽  
Gerald L. Murray ◽  
Glenda Fehler ◽  
Marcus Y. Chen ◽  
...  
2020 ◽  
pp. sextrans-2020-054726
Author(s):  
Eleanor M King ◽  
David Mesher ◽  
Pam Sonnenberg ◽  
Ezra Linley ◽  
Kavita Panwar ◽  
...  

ObjectivesMen who have sex with men (MSM) have an increased risk of human papillomavirus (HPV) infection and related diseases compared with men who have sex exclusively with women. From April 2018, there has been a phased roll-out of HPV vaccination offered to MSM aged up to 45 years old who are attending sexual health clinics and HIV clinics in England. The vaccine is most effective if delivered prior to HPV infection. We estimated the proportion of MSM with no current vaccine-type infection and no serological evidence of prior infection, in a study undertaken prior to vaccine introduction.MethodsWe conducted a cross-sectional study among 484 MSM aged 18–40 years old who attended a sexual health clinic in London between 2010 and 2012. We estimated the prevalence of current and past infection by testing for HPV DNA in anogenital samples and for serum antibodies to HPV16 and HPV18.ResultsThe median age was 30 years (IQR 25–35). The prevalence of HPV16 and HPV18 DNA was 13.2% and 6.2%, respectively. Seropositivity for HPV16 and HPV18 was 28.5% and 17.1%, respectively, with 11.4% seropositive for both types. Seropositivity for the same HPV type was strongly associated with anogenital DNA detection. 279 MSM (57.6%) tested negative for both HPV16 and HPV18 serology and were DNA negative for these two types; only 5 MSM (1.0%) were seropositive and DNA positive for both HPV types.ConclusionsThis is the first study to determine both the prevalence of HPV DNA in anogenital samples and HPV seroprevalence among MSM attending a sexual health clinic in the UK. Over half of MSM in this study had no evidence of a previous or current infection with either of the high-risk HPV types included in the quadrivalent vaccine, which supports the rationale for opportunistic HPV vaccination of MSM attending sexual health clinics.


2019 ◽  
Vol 96 (1) ◽  
pp. 55-57 ◽  
Author(s):  
Ross Liam Cameron ◽  
Kate Cuschieri ◽  
Kevin G J Pollock

ObjectivesA human papillomavirus (HPV) vaccination programme targeted towards men who have sex with men who are disproportionately affected by HPV anogenital infection and related disease was established in Scotland in July 2017. We aimed to establish a baseline HPV prevalence to assess the potential impact of the programme.MethodsResidual rectal swabs taken in a sexual health clinic (n=1 248) were tested for the presence of HPV and HPV-type prevalence was collated and stratified by age. Prevalence of HPV types included in the quadrivalent and nonavalent vaccines was specifically assessed.Results72.8% (95% CI 70.2% to 75.3%) of swabs were positive for HPV with 59.1% (95% CI 56.3% to 61.9%) of samples positive for at least one high-risk type. A least one of HPV 6, 11, 16 and 18 was detected in approximately half of the swabs. HPV prevalence generally increased with age but did not significantly differ between older age groups. The presence of more than one HPV type increased with age and over half of samples had multiple types present.ConclusionsWhile HPV prevalence in this population is high, the potential impact of the vaccination programme is substantial given that 50% are not infected with a vaccine type. Defining a preimmunisation baseline in this group will be important for longitudinal monitoring of impact.


2016 ◽  
Vol 43 (4) ◽  
pp. 243-248 ◽  
Author(s):  
Rebecca G. Nowak ◽  
Patti E. Gravitt ◽  
Xin He ◽  
Sosthenes Ketende ◽  
Wuese Dauda ◽  
...  

2019 ◽  
Vol 96 (1) ◽  
pp. 62-66
Author(s):  
Carol Strong ◽  
Huachun Zou ◽  
Nai-Ying Ko ◽  
Ya-Lun Liang ◽  
Wen-Wei Ku ◽  
...  

ObjectivesMen who have sex with men (MSM) are a highly neglected population in the current recommendation of girls-only human papillomavirus (HPV) vaccination programmes in many countries. To better assess the cost effectiveness of HPV vaccination among men requires data on the prevalence of HPV infection in MSM using a community sample, which is still sparse in several regions. We examined the prevalence of and factors associated with anogenital HPV infection among MSM in Taiwan.MethodsMSM 20 years of age and older were recruited from the community and social media in Taiwan in 2015–2016 and screened for HPV infection to detect 37 genotypes. MSM were seen at baseline and were/will be seen at 6, 12, 24 and 36 months. Men completed a questionnaire regarding their sexual experiences. Multivariable regression analyses were conducted to identify associated behavioural risk factors using the baseline data.ResultsA total of 253 MSM were recruited; 87 % were below 35 years of age. Diagnosis of HIV was reported in 4% of men; just over 20% had three or more anal sex partners in the past year. The prevalence of any tested HPV type was 29.4% at the anal site and 11% at the penile site. One quarter of MSM were infected with any of the 9-valent vaccine HPV types. Anal HPV detection was associated with having three or more receptive anal sex partners in the past year (adjusted odds ratio (aOR)=2.92, 95% CI 1.29 to 6.61) and having older sex partners (aOR=2.51, 95% CI 1.07 to 5.90).ConclusionsOur data provide the base to calculate the reproductive rate for HPV transmission in a low-risk community sample and cost-effectiveness to include men in HPV vaccination policies. Adding evidence from a community sample adds comprehensiveness for future estimates of disease transmission and vaccine effectiveness.


2019 ◽  
Author(s):  
Lenka Vodstrcil ◽  
Christopher Fairley ◽  
Catriona Bradshaw ◽  
Marcus Chen ◽  
Eric Chow

Vaccine ◽  
2020 ◽  
Vol 38 (13) ◽  
pp. 2849-2858 ◽  
Author(s):  
Yiguo Zhou ◽  
Yi-Fan Lin ◽  
Xiaojun Meng ◽  
Qibin Duan ◽  
Zhenyu Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document